Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP

被引：2
|
作者：
Higgins, Catherine A. [1 ]
Fox, Jennifer [1 ]
Majkut, Joanna [1 ]
Fiedler, Greti E. [1 ]
Roberts, Jamie [1 ]
Humphreys, Luke [1 ]
Boffey, Ray J. [2 ]
Perrior, Trevor R. [2 ]
Harrison, Timothy [1 ]
Longley, Daniel B. [1 ]
机构：
[1] Queens Univ Belfast, Belfast, Antrim, North Ireland
[2] Domainex Ltd, Saffron Walden CB10 1XL, Essex, England
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
基金：
英国惠康基金;
关键词：
D O I：
10.1158/1538-7445.AM2019-382
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
382
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway
    Lehal, Rajwinder
    Frismantas, Viktoras
    Urech, Charlotte
    Murone, Maximilien
    Weber, Dirk
    Bauer, Michael
    Bourquin, Jean-Pierre
    Radtke, Freddy
    CANCER RESEARCH, 2017, 77
  • [22] CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
    Lennox, A.
    Huang, F.
    Behrs, M. Kelly
    Pamulapati, C.
    Sales, M. Gonzalez
    Wan, Y.
    Sun, L.
    Berry, T.
    Feller, F.
    Morcos, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S64 - S64
  • [23] The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA
    Gu, Long
    Lingeman, Robert
    Yakushijin, Fumiko
    Sun, Emily
    Cui, Qi
    Chao, Jianfei
    Hu, Weidong
    Li, Hongzhi
    Hickey, Robert J.
    Stark, Jeremy M.
    Yuan, Yate-Ching
    Chen, Yuan
    Vonderfecht, Steven L.
    Synold, Timothy W.
    Shi, Yanhong
    Reckamp, Karen L.
    Horne, David
    Malkas, Linda H.
    CLINICAL CANCER RESEARCH, 2018, 24 (23) : 6053 - 6065
  • [24] DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY
    Lehal, R.
    Frismantas, V.
    Reinmuller, V.
    Turcatti, G.
    Bourquin, J. P.
    Radtke, F.
    HAEMATOLOGICA, 2016, 101 : 29 - 29
  • [25] RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
    Oronsky, Bryan
    Carter, Corey A.
    Caroen, Scott
    Scribner, Curtis
    Oronsky, Arnold
    Reid, Tony R.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [26] First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators
    Abdel-Rahman, Somaya A.
    Swiderek, Katarzyna
    Gabr, Moustafa T.
    RSC MEDICINAL CHEMISTRY, 2023, 14 (09): : 1767 - 1777
  • [27] First-in-class Small-molecule Inhibitor of Nox4 Promotes Reversal of Established Pulmonary Fibrosis
    Hecker, L.
    Kato, K.
    Papageorgiou, J.
    Gokhale, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [28] An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
    Ushijima, Miho
    Shiota, Masaki
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER SCIENCE, 2022, 113 (05) : 1731 - 1738
  • [29] AN ORAL FIRST-IN-CLASS SMALL MOLECULE RSK INHIBITOR SUPPRESSES AR VARIANTS AND TUMOR GROWTH IN PROSTATE CANCER
    Shiota, Masaki
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2022, 207 (05): : E98 - E99
  • [30] Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
    Workman, P.
    Clarke, P. A.
    Poele, R. Te
    Powers, M.
    Box, G.
    De Billy, E.
    Brandon, A. De Haven
    Hallsworth, A.
    Hayes, A.
    McCann, H.
    Sharp, S.
    Valenti, M.
    Raynaud, F. I.
    Eccles, S. A.
    Cheeseman, M.
    Jones, K.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S35 - S35
12345